Marco Meglio

Orelabrutinib has the potential to inhibit B cell and myeloid cell effector functions in the central nervous system and may provide a clinically meaningful benefit on progression in all forms of MS.

Use of prescription preventive medication was reported by less than 10% of participants throughout 3 years of follow-up after the completion of the CHAMP trial.

These study results highlight the interest in immunosuppressive therapy taken before or during pregnancy and to reduce the risk of relapse during pregnancy and 1 year postpartum.

The position statement considers the diagnosis of dementia, problems in decision making, symptoms and behavioral management, and the relationship between dementia care and society.

A significant proportion of survivors from ICH required substantial continuing care sector resources, namely complex continuing care, long-term care, rehabilitation services, and home care.

Invalid and valid performers did not differ regarding demographic, patient-reported, and disease-related outcomes.

The chief medical officer of Scholar Rock described how the investigational apitegromab aims to fill some of the current unmet needs for patients with spinal muscular atrophy.

Serum GFAP levels showed consistent correlations with disease activity and the largest area under the ROC curve to differentiate attacks from remissions in individuals with NMOSD.

ATH-1017, an investigational agent designed to focus on network recovery and synaptic signal transition in the brain, will be evaluated in patients on cognition, global, and functional assessments.

Total lesion volume and index lesion-related severity correlated with EDSS scores and cognitive performance, while volumetric cortical and subcortical gray matter correlated less strongly.

Fabio Nascimento, MD, clinical fellow at Massachusetts General Hospital, spoke about his research on the alarming lack of knowledge on SUDEP and its risk factors among trainees.

Each of the 2 identical twin phase 3 trials, titled ENSURE-1 and ENSURE-2, are expected to enroll approximately 1050 adult patients with active relapsing multiple sclerosis.

Since 2016, there has been consistent growth in the number of Alzheimer disease trials sponsored both in part and fully by academic medical centers and/or the National Institutes of Health.

The newly updated label language emphasizes the Alzheimer disease stages in which aducanumab was studied, with no additional changes made to its approval pathway.

Reduced cord cross-sectional area and a higher number of cervical cord lesions were the only significant predictors of an EDSS score equal to 6.0.

The chief medical officer of Scholar Rock provided background on the company’s investigational SMA treatment and its clinical benefit when applied with nusinersen (Spinraza; Biogen).

The effect pridopidine had on reducing mutant HTT-induced endoplasmic reticulum stress via the activation of sigma-1 receptor provided additional evidence of its therapeutic potential.

The basis for the approval was data from the phase 3 SAkuraSky and SAkuraStar studies, which combined included more than 170 patients who were treated with either satralizumab or placebo.

The pediatric headache specialist at NYU Langone discussed adjusting management approaches to pediatric headache and the current state of research within the space.

The differences between the obstructive sleep apnea categories became more apparent when a shorter epoch-to-epoch interval was used to assess this deep learning-based signal.

Both high PiB and low entorhinal fluorodeoxyglucose as inclusion criteria reduced 3-fold the number of participants needed in a hypothetical trial compared to using only high PiB.

Patients who received high-dose blarcamesine experienced a 14.51-point MDS-UPDRS total score improvement compared to placebo in a phase 2 study of the Anavex Life Sciences agent.

Longer exposure to disease-modifying therapy over the follow-up period reduced the risk of disability worsening among pregnant people with multiple sclerosis.

The pediatric headache specialist at NYU Langone discussed how pediatric migraine is currently treated, the signs and symptoms associated, and whether awareness levels are where they need to be.

Patients will be randomized to either 120-mg galcanezumab or 75-mg rimegepant and will be evaluated on the percentage of patients achieving a 50% reduction in monthly migraine headache days.

Hermona Soreq, PhD, discusses the complexities of aducanumab’s FDA approval, her initial reaction to the news, and whether it might be greenlit by other country’s regulators.

An excellent epilepsy outcome was achieved in 66% of cases over a median follow-up of 41 months and was not significantly associated with the type of surgery undergone.

The treatment device from Theranica also demonstrated a positive impact on patients who experienced menstrual cramps or pelvic pain.

Eli Lilly plans on submitting a biologics license application for donanemab under the accelerated approval pathway based on data from the phase 2 TRAILBLAZER-ALZ study.

Calli L. Cook, NP, DNP, nurse practitioner, Woodruff School of Nursing, Emory University, detailed her vision for creating change within the neurology field by incorporating advanced practice clinicians.